Ocular Therapeutix (NASDAQ:OCUL) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Ocular Therapeutix (NASDAQ:OCUL) issued its earnings results on Monday. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.06), FiscalAI reports. The company had revenue of $12.87 million during the quarter, compared to analyst estimates of $14.27 million. Ocular Therapeutix had a negative return on equity of 56.26% and a negative net margin of 648.64%. The company’s quarterly revenue was down 11.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.38) earnings per share.

Here are the key takeaways from Ocular Therapeutix’s conference call:

• Ocular said it remains on track to submit AXPAXLI’s wet AMD NDA in Q4 2026, following a positive pre-NDA meeting and alignment with the FDA on its submission plan. The company expects the package to include SOL-1 efficacy, interim SOL-R safety, and repeat-dose data from more than 300 patients.
• Management highlighted SOL-1 results showing durable disease control after one injection, including about two-thirds of patients remaining rescue-free through week 52 in a challenging patient population. Based on these findings, Ocular is extending SOL-X dosing intervals from 24 to 48 weeks to study annual maintenance treatment.
• Ocular changed SOL-R’s primary efficacy endpoint from week 56 to week 40 so all patients can complete the assessment before the planned safety-data unmasking; the company said the change is FDA-aligned and carries a minimal alpha penalty. SOL-R remains masked through week 96, with topline results expected in Q1 2028.
• The company is building launch capabilities and said it has held pre-approval discussions with all of its top-priority payer accounts, covering about 84% of commercial lives. Management believes AXPAXLI could address the maintenance-treatment segment, though approval and adoption are not assured.
• Ocular ended Q3 with $530.6 million in cash and expects its runway to extend into 2028, but that estimate excludes the full anticipated costs of commercializing AXPAXLI.

Ocular Therapeutix Stock Performance

OCUL stock opened at $6.64 on Wednesday. Ocular Therapeutix has a twelve month low of $6.00 and a twelve month high of $16.44. The company has a quick ratio of 13.03, a current ratio of 13.10 and a debt-to-equity ratio of 0.14. The company has a market cap of $1.46 billion, a P/E ratio of -4.55 and a beta of 1.22. The business’s fifty day moving average is $8.25 and its 200-day moving average is $8.97.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on OCUL. HC Wainwright raised their price objective on shares of Ocular Therapeutix from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Thursday, October 15th. Royal Bank Of Canada reissued an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday, September 29th. UBS Group assumed coverage on shares of Ocular Therapeutix in a research report on Sunday, October 11th. They set a “buy” rating and a $14.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a research report on Monday, October 19th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $23.83.

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, insider Peter Kaiser sold 9,990 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $7.05, for a total value of $70,429.50. Following the transaction, the insider owned 254,388 shares of the company’s stock, valued at approximately $1,793,435.40. This represents a 3.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Todd Anderman sold 11,984 shares of the stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $7.29, for a total value of $87,363.36. Following the completion of the transaction, the insider directly owned 140,484 shares in the company, valued at $1,024,128.36. The trade was a 7.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 98,090 shares of company stock valued at $787,920 over the last quarter. 3.10% of the stock is owned by corporate insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.